{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T14:15:30Z","timestamp":1725977730246},"publisher-location":"New York, NY","reference-count":17,"publisher":"Springer New York","isbn-type":[{"type":"print","value":"9781493978465"},{"type":"electronic","value":"9781493978472"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1007\/978-1-4939-7847-2_16","type":"book-chapter","created":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T13:26:51Z","timestamp":1525699611000},"page":"207-222","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Quantitative Systems Pharmacology Approach to Infer Pathways Involved in Complex Disease Phenotypes"],"prefix":"10.1007","author":[{"given":"Mark E.","family":"Schurdak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fen","family":"Pei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy R.","family":"Lezon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Carlisle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Lansing","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Stern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"16_CR1","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1177\/1087057116635818","volume":"21","author":"AM Stern","year":"2016","unstructured":"Stern AM, Schurdak ME, Bahar I, Berg JM, Taylor DL (2016) A perspective on implementing a quantitative systems pharmacology platform for drug discovery and the advancement of personalized medicine. J Biomol Screen 21:521\u2013534","journal-title":"J Biomol Screen"},{"key":"16_CR2","unstructured":"Sorger PK, Allerheiligen SRB, Abernethy DR, Altman RB, Brouwer KLR, Califano A et al. (2011) Quantitative and systems pharmacology in the post-genomic era: new approaches to discovering drugs and understanding therapeutic mechanisms. NIH White Paper, QSP Workshop Group"},{"key":"16_CR3","unstructured":"Taylor DL (2012) A new vision of drug discovery and development. European Pharmaceutical Review 17(6)"},{"key":"16_CR4","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ymeth.2015.10.007","volume":"96","author":"A Gough","year":"2016","unstructured":"Gough A, Shun TY, Taylor DL, Schurdak M (2016) A metric and workflow for quality control in the analysis of heterogeneity in phenotypic profiles and screens. Methods 96:12\u201326","journal-title":"Methods"},{"key":"16_CR5","doi-asserted-by":"publisher","first-page":"e102678","DOI":"10.1371\/journal.pone.0102678","volume":"9","author":"AH Gough","year":"2014","unstructured":"Gough AH, Chen N, Shun TY, Lezon TR, Boltz RC, Reese CE et al (2014) Identifying and quantifying heterogeneity in high content analysis: application of heterogeneity indices to drug discovery. PLoS One 9:e102678","journal-title":"PLoS One"},{"key":"16_CR6","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nrg1317","volume":"5","author":"M Bredel","year":"2004","unstructured":"Bredel M, Jacoby E (2004) Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet 5:262\u2013275","journal-title":"Nat Rev Genet"},{"key":"16_CR7","doi-asserted-by":"publisher","first-page":"10543","DOI":"10.1021\/ja035413p","volume":"125","author":"SJ Haggarty","year":"2003","unstructured":"Haggarty SJ, Clemons PA, Schreiber SL (2003) Chemical genomic profiling of biological networks using graph theory and combinations of small molecule perturbations. J Am Chem Soc 125:10543\u201310545","journal-title":"J Am Chem Soc"},{"key":"16_CR8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.drudis.2006.08.013","volume":"11","author":"CJ Harris","year":"2006","unstructured":"Harris CJ, Stevens AP (2006) Chemogenomics: structuring the drug discovery process to gene families. Drug Discov Today 11:880\u2013888","journal-title":"Drug Discov Today"},{"key":"16_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.chembiol.2015.11.008","volume":"23","author":"BK Wagner","year":"2016","unstructured":"Wagner BK, Schreiber SL (2016) The power of sophisticated phenotypic screening and modern mechanism-of-action methods. Cell Chem Biol 23:3\u20139","journal-title":"Cell Chem Biol"},{"key":"16_CR10","doi-asserted-by":"crossref","unstructured":"Pei F, Li H, Henderson MJ, Titus SA, Jadhv A, Simeonov A et al. (2017) Connecting Neuronal Cell Protective Pathways and Drug Combinations in a Huntington's Disease Model through the Application of Quantitative Systems Pharmacology.\u00a0Scientific Reports 7:17803","DOI":"10.1038\/s41598-017-17378-y"},{"key":"16_CR11","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/hmg\/9.19.2799","volume":"9","author":"F Trettel","year":"2000","unstructured":"Trettel F (2000) Dominant phenotypes produced by the HD mutation in STHdhQ111 striatal cells. Hum Mol Genet 9:2799\u20132809","journal-title":"Hum Mol Genet"},{"key":"16_CR12","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang JH, Chung TD, Oldenburg KR (1999) A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 4:67\u201373","journal-title":"J Biomol Screen"},{"key":"16_CR13","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/1087057114521867","volume":"19","author":"W Zhao","year":"2014","unstructured":"Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H (2014) A new bliss independence model to analyze drug combination data. J Biomol Screen 19:817\u2013821","journal-title":"J Biomol Screen"},{"key":"16_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","volume":"22","author":"TC Chou","year":"1984","unstructured":"Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27\u201355","journal-title":"Adv Enzyme Regul"},{"key":"16_CR15","first-page":"207","volume":"115","author":"TC Chou","year":"1981","unstructured":"Chou TC, Talalay P (1981) Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. FEBS J 115:207\u2013216","journal-title":"FEBS J"},{"key":"16_CR16","volume-title":"Assay guidance manual","author":"W Buchser","year":"2004","unstructured":"Buchser W, Collins M, Garyantes T, Guha R, Haney S, Lemmon V et al (2004) Assay development guidelines for image-based high content screening, high content analysis and high content imaging. In: Sittampalam GS, Coussens NP, Brimacombe K et al (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD"},{"key":"16_CR17","volume-title":"Assay guidance manual","author":"MA Bray","year":"2004","unstructured":"Bray MA, Carpenter A (2004) Advanced assay development guidelines for image-based high content screening and analysis. In: Sittampalam GS, Coussens NP, Brimacombe K et al (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD"}],"container-title":["Methods in Molecular Biology","Phenotypic Screening"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-4939-7847-2_16","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,7]],"date-time":"2018-05-07T13:27:43Z","timestamp":1525699663000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-1-4939-7847-2_16"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9781493978465","9781493978472"],"references-count":17,"URL":"https:\/\/doi.org\/10.1007\/978-1-4939-7847-2_16","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"type":"print","value":"1064-3745"},{"type":"electronic","value":"1940-6029"}],"subject":[],"published":{"date-parts":[[2018]]}}}